(Q33357014)

26 July 2017

Hematologic effects of linezolid in young children (English)

1 reference

26 July 2017

1 reference

Timothy Townsend

2

1 reference

26 July 2017

Wanda Wenman

3

1 reference

26 July 2017

Maria Rayo Morfin

5

1 reference

26 July 2017

Barbara Edge-Padbury

6

1 reference

26 July 2017

Sharon Naberhuis-Stehouwer

7

1 reference

26 July 2017

H. Cody Meissner

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14520145

16 March 2024

Sheldon L. Kaplan

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14520145

16 March 2024

Jon B. Bruss

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14520145

16 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14520145

16 March 2024

publication date

1 September 2003

1 reference

full work available at URL

26 July 2017

https://journals.lww.com/10.1097/01.inf.0000087021.20838.d9

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087021.20838.D9

Pediatric Infectious Disease Journal

16 March 2024

published in

1 reference

26 July 2017

22

1 reference

26 July 2017

S186-92

1 reference

26 July 2017

9 Suppl

1 reference

Linezolid: the first oxazolidinone antimicrobial

26 July 2017

1

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087021.20838.D9

Hematologic effects of linezolid: summary of clinical experience

16 March 2024

2

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087021.20838.D9

Linezolid and reversible myelosuppression

16 March 2024

4

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087021.20838.D9

Linezolid and reversible myelosuppression

16 March 2024

5

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087021.20838.D9

Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid

16 March 2024

6

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087021.20838.D9

Linezolid-Induced anemia and thrombocytopenia

16 March 2024

7

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087021.20838.D9

Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Linezolid Pediatric Pneumonia Study Group

16 March 2024

8

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087021.20838.D9

Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children

16 March 2024

9

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087021.20838.D9

Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children

16 March 2024

10

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087021.20838.D9

Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections

16 March 2024

11

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087021.20838.D9

In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci

16 March 2024

12

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087021.20838.D9

Autoimmune hemolytic anemia

16 March 2024

15

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087021.20838.D9

16 March 2024

Drug-induced anaemias

16

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087021.20838.D9

Interaction of chloramphenicol and metabolites with colony stimulating factors: possible role in chloramphenicol-induced bone marrow injury

16 March 2024

20

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087021.20838.D9

Chloramphenicol and bone marrow mitochondria

16 March 2024

21

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087021.20838.D9

Mitochondrial lesions in reversible erythropoietic depression due to chloramphenicol

16 March 2024

22

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087021.20838.D9

Effect of Trimethoprim on Folate Metabolism in Human Bone Marrow

16 March 2024

23

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087021.20838.D9

Drug-induced thrombocytopenia: a systematic review of published case reports

16 March 2024

24

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087021.20838.D9

Letter: Methicillin-associated thrombocytopenia

16 March 2024

25

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087021.20838.D9

Immunological effect of co-trimoxazole on platelets

16 March 2024

26

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087021.20838.D9

Thrombocytopenia due to vancomycin

16 March 2024

27

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087021.20838.D9

Non-malignant neutropenia

16 March 2024

30

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087021.20838.D9

16 March 2024

Identifiers

1 reference

26 July 2017

1 reference